Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can less radiation be just as good for hodgkin lymphoma?

NCT ID NCT07256158

Disease control Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This phase 3 trial is testing whether a lower dose of radiation (20 Gy) is as effective as the standard dose (30 Gy) for people with early-stage, unfavorable Hodgkin lymphoma. Only patients whose cancer shows a complete metabolic response after two cycles of chemotherapy will be included. The goal is to reduce side effects while maintaining the same level of cancer control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy (involved site radiotherapy)
What this could lead to
If successful, this could allow many Hodgkin lymphoma patients to receive a lower, safer dose of radiation without reducing the chance of keeping the cancer from coming back.
What could go wrong
This is a non-inferiority trial, so the lower dose might prove slightly less effective. The results apply only to patients who already had a good response to two cycles of chemotherapy, not everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 518 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Aug 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years; * Histologically confirmed classical HL stage I, II unfavorable according to GHSG criteria; * Patient with any nodal mass ≥ than 10 cm can be included * No previous treatment for Hodgkin lymphoma; * ECOG performance status 0 to 2; * Presence of FDG-avid lymphoma lesions on baseline PET scan; * Subject understands and voluntarily signs the informed consent form approved by the Independent Ethics Committee (IEC), prior to the initiation of any screening or study-specific procedures; * Adequate organ and marrow function as defined below: * absolute neutrophil count \> 1.0 x109/L * platelet count \> 75 x109/L * Total bilirubin \< 2 mg/dl without a pattern consistent with Gilbert's syndrome * Aspartate Transaminase and Alanine Transaminase (AST/ALT) \< 3.0 X institutional Upper Limits of Normality (ULN) * Creatinine within normal institutional limits or creatinine clearance \> 50 mL/min * Women of childbearing potential must agree to use a highly effective method of contraception (oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device) from the signature of informed consent until six months after the last dose of treatment; * Men must agree to use a highly effective method of contraception (barrier contraception or abstinence, when this is in line with the usual lifestyle of the subject) from the signature of informed consent until six months after the last dose of treatment; * Women of childbearing potential must have a negative serum pregnancy test at screening. Exclusion Criteria: * Patients who meet any of the following criteria are not eligible to enroll: * Stage II B- III- IV * Hodgkin Lymphoma as "composite lymphoma" or nodular lymphocyte prevalence histological subtype * Active HBV and HCV infection * HIV seropositivity * Pre-treatment with chemotherapy or radiation therapy * Malignant disease within the last 5 years (excluding basal skin tumors and carcinoma in situ of the cervix) * Women who are pregnant or breast feeding * Absence of FDG-avid lymphoma lesions on baseline PET scan * Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Classical Hodgkin lymphoma stage I, II unfavorable are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hodgkin lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    38 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O. Ospedale S. Maria della Misericordia - Ematologia

    NOT_YET_RECRUITING

    Perugia, Italy

  • A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia

    NOT_YET_RECRUITING

    Palermo, Italy

  • A.O. S. Croce e Carle - S.C. Ematologia

    NOT_YET_RECRUITING

    Cuneo, Italy

  • A.O. Santa Maria - S.C. Oncoematologia

    NOT_YET_RECRUITING

    Terni, Italy

  • A.O.R.N. G Moscati - U.O.C. Ematologia e Terapie cellulari avanzate

    NOT_YET_RECRUITING

    Avellino, Italy

  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia

    RECRUITING

    Torino, Italy

  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U

    NOT_YET_RECRUITING

    Torino, Italy

  • A.O.U. Ospedale Maggiore della Carità - S.C.D.U. Ematologia

    NOT_YET_RECRUITING

    Novara, Italy

  • A.O.U. Policlinico Umberto I - U.O.C Ematologia

    NOT_YET_RECRUITING

    Roma, Italy

  • A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. Ematologia

    NOT_YET_RECRUITING

    Alessandria, Italy

  • A.O.U. Sant'Andrea - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Roma, Italy

  • A.O.U. Senese - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Siena, Italy

  • A.O.U. di Padova - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Padova, Italy

  • A.O.U.I. di Verona - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Verona, Italy

  • A.S.L. Toscana Centro - SOC Oncoematologia

    NOT_YET_RECRUITING

    Florence, Italy

  • A.S.U. Friuli Centrale - Clinica Ematologica

    NOT_YET_RECRUITING

    Udine, Italy

  • A.S.U. Giuliano Isontina - S.C. Ematologia

    NOT_YET_RECRUITING

    Trieste, Italy

  • ARNAS "Brotzu" P.O. Businco - S.C. Ematologia e TMO

    NOT_YET_RECRUITING

    Cagliari, Italy

  • ARNAS Garibaldi - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Catania, Italy

  • ASL Latina Ospedale S. Maria Goretti - UOC Ematologia con trapianto

    NOT_YET_RECRUITING

    Latina, Italy

  • ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia

    NOT_YET_RECRUITING

    Milan, Italy

  • ASST Papa Giovanni XXIII - S.C. Ematologia

    NOT_YET_RECRUITING

    Bergamo, Italy

  • ASST Spedali Civili - S.C. Ematologia

    NOT_YET_RECRUITING

    Brescia, Italy

  • AUSL IRCCS Arcispedale S. Maria Nuova - S.C. Ematologia

    NOT_YET_RECRUITING

    Reggio Emilia, Italy

  • AUSL di Piacenza Ospedale Guglielmo da Saliceto - U.O.C. Ematologia e centro trapianti

    NOT_YET_RECRUITING

    Piacenza, Italy

  • AUSL di Ravenna Osp. S. Maria delle Croci - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Ravenna, Italy

  • Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

    NOT_YET_RECRUITING

    Florence, Italy

  • Clinica Humanitas Gavazzeni - U.O. Oncologia Medica

    NOT_YET_RECRUITING

    Bergamo, Italy

  • Fondazione Policlinico Campus Bio-Medico - U.O.C. Ematologia e trapianto di cellule staminali

    NOT_YET_RECRUITING

    Roma, Italy

  • I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1

    NOT_YET_RECRUITING

    Padova, Italy

  • I.R.C.C.S. Istituto di Candiolo - FPO

    NOT_YET_RECRUITING

    Candiolo, Italy

  • IRCCS Centro Riferimento Oncologico - S.O.C. Oncologia medica e dei tumori immuno-correlati

    NOT_YET_RECRUITING

    Aviano, Italy

  • IRCCS Fondazione Casa Sollievo della Sofferenza - UOC Ematologia e Trapianto di Cellule Staminali Ematopoietiche

    NOT_YET_RECRUITING

    San Giovanni Rotondo, Italy

  • IRCCS Fondazione Istituto Nazionale Tumori - S.C. Ematologia

    NOT_YET_RECRUITING

    Milan, Italy

  • IRCCS Fondazione Policlinico S. Matteo - S.C. Ematologia 1

    NOT_YET_RECRUITING

    Pavia, Italy

  • IRCCS Humanitas - U.O. Ematologia

    NOT_YET_RECRUITING

    Rozzano, Italy

  • IRCCS Policlinico S. Martino - U.O. Ematologia e terapie cellulari

    NOT_YET_RECRUITING

    Genova, Italy

  • ULSS 2 Ospedale Ca' Foncello - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Treviso, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.